Loading
Dermapharm Holding SE Stock: price and insider trades · Germany
No insider purchase over the last 90 days. The latest was filed 15 May 2026.
Dermapharm Holding SE: what insiders have been doing
Dermapharm Holding SE, classified in the Healthcare & Pharma sector, is a listed company based in Grünwald, Germany, founded in 1991. Its latest reported headcount is 3,497 employees (2023). Its insiders report their share dealings to BaFin. Over the twelve months to 18 October 2026, 4 filings were filed, from 2 insiders.
The flow runs one way only: 2 insiders bought (4 purchases totalling €108.0M) and nobody sold on the market. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Among those who bought: 1 senior executive. Themis Beteiligungs-Aktiengesellschaft filed the largest purchase, €53.8M, on 10 December 2025.
In all, 1 purchase was made within 30 days of a purchase by another insider of the company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 15 May 2026, which is 155 days ago. Filings reach the BaFin feed a median of 2 days after the trade. For comparison, MAR article 19 gives managers three business days to notify a trade.
Across the 287 companies tracked on its exchange, the median is 5 filings; at 4 filings, this issuer sits below that mark. Our records for Dermapharm Holding SE go back to 2025, with 8 purchases and no sales on the open market in total.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by BaFin. They describe what insiders did and are not a recommendation.
Insider Decl.
8
Thresholds
n/a
Buy Volume
€112M
8 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleThemis Beteiligungs-Aktiengesellschaft3 buys
Dr. Hans-Georg Feldmeier2 buys
Anja Schorn1 buy
Christof Dreibholz1 buy
Dr. Andreas Eberhorn1 buy
Wilhelm Beier1 buy
Since the insiders bought
- -23.5%Entry €49.70 · Close 16 Oct 2026 €38.00
- -0.7%Entry €38.25 · Close 16 Oct 2026 €38.00
- +30.0%Entry €35.05 · Close at T+365 €45.55
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Dermapharm Holding SE Buy (bullish), based on 4 analysts. Average price target: €51.00.
Fundamental score
Ranked 3,048 of 24,158 companies
71.7
score / 100
Value73
Quality71
FCF yld9.7%
Earn yld6.9%
EV/EBITDA9.2x
ROE26%
Gross mgn67%
Net mgn11%
Debt/EBITDA3.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€39.00
Analyst consensus
4 analystsBuy
€44.00Target €51.00(+31%)€60.00
Income statement
Revenue€1.2B
Gross profit€782.9M67% margin
EBITDA€324.7M28% margin
Net income€132.4M12.4% margin
Valuation
PER (trailing)14.1x
PER (forward)13.1x
P/Book3.6x
Beta0.85
Balance sheet & cash
Market cap€1.9B
Total debt€1.1B
Free Cash Flow€187.0M
Debt / Equity219%
Profitability & ownership
ROE25.6%
ROA7.1%
% insiders89.3%
% institutions8.2%
Last declaration on 15 May 2026
Declarations8 total
380,000 shares@ €46.830.90% mcap16.5% of flowShareISIN DE000A2GS5D8BAFIN:40026678-aeb98097defa
Canonical exit: 12 Aug 2026 (T+90)
2,500.13 shares@ €38.33100.0% of flowShareTradegate ExchangeISIN DE000A2GS5D8BAFIN:40026678-d9d9b1da1999
Canonical exit: 5 Apr 2026 (T+90)
1,438,000 shares@ €37.4349.9% of flowShareISIN DE000A2GS5D8BAFIN:40026678-5db2d1311eba
Canonical exit: 8 Mar 2026 (T+90)
1,080,160.906 shares@ €33.5633.6% of flowShareISIN DE000A2GS5D8BAFIN:40026678-6ea1471a9fe2
Canonical exit: 28 Jan 2026 (T+90)
100,000 shares@ €34.94100.0% of flowShareISIN DE000A2GS5D8BAFIN:40026678-1b9205129a7e
Canonical exit: 1 Oct 2025 (T+90)
1,492 shares@ €33.50100.0% of flowShareISIN DE000A2GS5D8BAFIN:40026678-611540c3f04a
Canonical exit: 21 Sept 2025 (T+90)
1,000 shares@ €35.10100.0% of flowShareISIN DE000A2GS5D8BAFIN:40026678-1e7542f70a76
Canonical exit: 2 Sept 2025 (T+90)
2,799.976 shares@ €35.62100.0% of flowShareDeutsche Börse FrankfurtISIN DE000A2GS5D8BAFIN:40026678
Canonical exit: 31 Aug 2025 (T+90)
8 of 8 declarations
About Dermapharm Holding SE
Dermapharm Holding SE is a German-listed pharmaceutical and healthcare group traded on Xetra/Frankfurt (DAX/MDAX/SDAX), headquartered in Grünwald near Munich, Germany. Founded in 1991, the company has built an integrated business model spanning in-house development, manufacturing, quality management, logistics and distribution. From an equity research perspective, Dermapharm is best understood as a specialty healthcare platform focused on branded medicines and regulated consumer-health assets rather than a pure commodity generics player. The group states that it manufactures the large majority of its pharmaceutical portfolio internally, which is an important industrial and margin-supportive differentiator.
Dermapharm’s operations are structured into three segments. “Branded pharmaceuticals” is the core segment and covers proprietary, branded medicines developed and commercialized by the group across therapeutic areas such as dermatology, allergy, pain, women’s health and other prescription/OTC niches. “Other healthcare products” includes food supplements, herbal medicines, cosmetics, medical devices, herbal extracts and medicinal cannabis. This segment has been expanded through international acquisitions, notably Arkopharma in France, Euromed in Spain, Montavit in Austria and Cernelle in Sweden. The third segment, “Parallel import business”, is led by axicorp and focuses on the parallel import of originator pharmaceuticals, a business that tends to be more sensitive to pricing spreads, reimbursement dynamics and portfolio optimization.
Read moreShow less
Geographically, Dermapharm remains firmly anchored in Germany, its key industrial and commercial base, while also operating production, development and distribution sites across Europe, as well as in the United States and parts of Asia. The company emphasizes its broad footprint in Europe, which supports both commercial diversification and manufacturing resilience. Dermapharm also highlights a portfolio of more than 1,300 marketing authorizations and more than 380 active pharmaceutical ingredients in its core branded-pharmaceuticals and healthcare activities, reinforcing the depth of its product base and launch capabilities.
Recent developments are notable. On 10 March 2026, Dermapharm published preliminary 2025 figures showing revenue of EUR 1,165.0 million, down modestly year on year, while adjusted EBITDA increased to EUR 324.8 million and the adjusted margin improved. The company also announced a public share buyback offer for up to 4.3 million shares at EUR 42.00 per share. This followed a 2025 trading year in which management consistently pointed to stable underlying profitability despite portfolio adjustments in parallel imports. For investors, the key appeal lies in a defensive healthcare profile, strong cash-generation characteristics, a meaningful branded-product platform and ongoing capital allocation discipline.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
